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Abstract
Background: Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass in a variety of
disorders, including the muscular dystrophies, cachexia, and sarcopenia. Previously described approaches to
blocking myostatin signaling include injection delivery of inhibitory propeptide domain or neutralizing
antibodies.
Methodology/Principal Findings: Here we describe a unique method of myostatin inhibition utilizing
recombinant adeno-associated virus to overexpress a secretable dominant negative myostatin exclusively in
the liver of mice. Systemic myostatin inhibition led to increased skeletal muscle mass and strength in control
C57 Bl/6 mice and in the dystrophin-deficient mdx model of Duchenne muscular dystrophy. The mdx soleus,
a mouse muscle more representative of human fiber type composition, demonstrated the most profound
improvement in force production and a shift toward faster myosin-heavy chain isoforms. Unexpectedly, the
11-month-old mdx diaphragm was not rescued by long-term myostatin inhibition. Further, mdx mice treated
for 11 months exhibited cardiac hypertrophy and impaired function in an inhibitor dose–dependent manner.
Conclusions/Significance: Liver-targeted gene transfer of a myostatin inhibitor is a valuable tool for
preclinical investigation of myostatin blockade and provides novel insights into the long-term effects and
shortcomings of myostatin inhibition on striated muscle.
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Background: Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass in a variety of disorders,
including the muscular dystrophies, cachexia, and sarcopenia. Previously described approaches to blocking myostatin
signaling include injection delivery of inhibitory propeptide domain or neutralizing antibodies.
Methodology/Principal Findings: Here we describe a unique method of myostatin inhibition utilizing recombinant adeno-
associated virus to overexpress a secretable dominant negative myostatin exclusively in the liver of mice. Systemic
myostatin inhibition led to increased skeletal muscle mass and strength in control C57 Bl/6 mice and in the dystrophin-
deficient mdx model of Duchenne muscular dystrophy. The mdx soleus, a mouse muscle more representative of human
fiber type composition, demonstrated the most profound improvement in force production and a shift toward faster
myosin-heavy chain isoforms. Unexpectedly, the 11-month-old mdx diaphragm was not rescued by long-term myostatin
inhibition. Further, mdx mice treated for 11 months exhibited cardiac hypertrophy and impaired function in an inhibitor
dose–dependent manner.
Conclusions/Significance: Liver-targeted gene transfer of a myostatin inhibitor is a valuable tool for preclinical investigation
of myostatin blockade and provides novel insights into the long-term effects and shortcomings of myostatin inhibition on
striated muscle.
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Introduction
Myostatin or Growth Differentiation Factor 8 (GDF-8) is a
member of the pleiotrophic transforming growth factor b family
and is a potent negative regulator of skeletal muscle mass.
Myostatin is highly conserved across species and when functionally
inactivated results in profound increases in skeletal muscle mass in
cows, dogs, sheep, mice and humans [1]. Conversely, ectopic
overexpression of myostatin induces skeletal muscle atrophy [2]. A
multitude of experiments have demonstrated that the absence of
myostatin due to genetic deletion or inhibition results in increased
muscle mass [3–6]. While the effect of myostatin inhibition on
skeletal muscle mass and morphology is dependent on the route,
timing and mechanism of blockade, invariably there is an increase
in muscle size due to the growth of muscle fibers (hypertrophy)
and/or an increased number of muscle fibers (hyperplasia). When
myostatin is genetically deleted or inhibited by transgenic
expression of the myostatin binding protein follistatin, there is a
more profound increase in muscle mass and both hypertrophy and
hyperplasia of fibers is observed [4,5]. Postnatally, myostatin
inhibition achieved by neutralizing antibodies directed against
myostatin administered in normal C57 Bl/6 mice and in the mdx
mouse model of Duchenne muscular dystrophy leads to muscle
growth due to hypertrophy and not hyperplasia [3,6].
A common feature of murine dystrophic animal models is the
compensatory regeneration of muscle fibers due to satellite cell
activation, proliferation and fusion to existing muscle fibers or de
novo formation of myofibers. Hence myostatin based therapies hold
great promise for the muscular dystrophies due to their ability to
increase fiber size, enhance regeneration and regulate muscle
fibrosis [3,7,8]. Myostatin inhibition has resulted in significant
amelioration of dystrophic pathology in a mild dystrophic model
(mdx), mixed findings in a severe dystrophic model (dsg) or no
improvement in severe dystrophic models (gsg, dy) [5,9–11]. That
myostatin inhibition does not improve severe muscular dystrophy
is not surprising as myostatin cannot correct the underlying genetic
defect. For the muscular dystrophies, myostatin inhibition could be
utilized to augment correction of the primary defect by promoting
short term gains of muscle mass. Increased muscle mass may
protect against contraction induced damage by reducing the
amount of muscle recruited to produce a given amount of force
[12]. Myostatin modulation also has therapeutic potential for
disease states that involve the loss of normal muscle mass, such as
cancer cachexia, disuse atrophy, sarcopenia and microgravity
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exposure. However, there is the possibility that myostatin
inhibition in the heart could interfere with cardiac adaptation to
underlying cardiac disease that may occur with aging and a subset
of the muscular dystrophies.
Previous preclinical studies in the mdx mouse model of
Duchenne muscular dystrophy targeting the myostatin pathway
have utilized neutralizing antibodies, myostatin propeptide
injection and recombinant adeno-associated virus (AAV) mediated
expression of a myostatin inhibitor from multiple tissues [5,13,14].
These studies all showed skeletal muscle improvement although
the animals were only followed for 3–4 months following initiation
of treatment. As the muscular dystrophies result in progressive
pathology of skeletal muscle, long term studies are crucial to
determine if proposed treatments will correct the pathology over
time and to assess the effect of myostatin inhibition on cardiac
function. At nine months of age mdx mice first develop signs of a
progressive dilated cardiomyopathy, an age that was not analyzed
in these studies [5,13,14]. Qiao et al. recently reported that the
AAV mediated expression of a mutated myostatin propeptide
increases muscle size and improves pathology in mdx animals [14].
While they suggested that this was due to liver secretion,
immunoblotting did not show expression of the propeptide in
the liver and RT-PCR showed expression of the transgene in the
heart as well as the liver. As a ubiquitous promoter was used in this
study, it is possible that propeptide is not being expressed in the
liver but from the heart as well as other unscreened skeletal
muscles. Haidet et al. used intramuscular injections of AAV to
overexpress endogenous proteins that inhibit myostatin [15]. A
limitation of this study is that none of the inhibitors was specific for
myostatin. For example, follistatin and follistatin like related gene
(FLRG) bind to activin in addition to myostatin and GDF
associated serum protein 1 (GASP1) also contains protease
domains [16–19]. The observed beneficial effects on muscle
growth may depend on signaling pathways other than myostatin
that are not specific to muscle, and the modulation of non-muscle
tissue physiology may limit clinical application.
While there has been considerable interest in utilizing myostatin
inhibition to ameliorate muscular dystrophy and other disorders,
comprehensive long term studies of postnatal myostatin inhibition
have not yet been reported. An evaluation including functional
assessment of slow and fast muscle types as well as the diaphragm
and heart is lacking. The diaphragm is the most severely
dystrophic skeletal muscle in the mdx mouse and is the mouse
muscle most representative of human disease progression. Direct
injection of all of these tissues is not possible and dystrophic muscle
does not support long term AAV transduction without membrane
stabilization. The loss of AAV transduction over time is most likely
due to muscle fiber turnover as evidenced by the loss of AAV
mediated IGF expression after four months in mdx muscle
(unpublished observations by E.R. Barton and H.L. Sweeney)
and a similar loss of AAV mediated myostatin propeptide
expression after six weeks in the highly regenerative alpha-
sarcoglycan null model [20,21].
To address these questions we developed a method that
achieves persistent myostatin inhibition through a single dose of
AAV to overexpress a novel myostatin inhibitor from the liver of
C57 Bl/6 and mdx mice. C57 Bl/6 mice were treated as neonates
or young adults then examined three months post injection to
determine the effect of myostatin inhibition on muscle mass in
normal animals. Mdx mice were injected as neonates or one month
of age and examined at four and eleven months of age to assess the
effect of myostatin inhibition at early and later stages of muscle
pathology. A functional and histological assessment of the soleus,
extensor digitorum longus (EDL), diaphragm and heart were
made to determine the effect of myostatin inhibition systemically.
These findings have important implications for future therapies
that utilize the myostatin pathway and for the regulatory role of
myostatin in skeletal and cardiac muscle.
Results
To express persistently a circulating myostatin inhibitor, a
dominant negative myostatin propeptide was engineered
(dnMstat), paired with a liver specific promoter (a1-antitrypsin
promoter with ApoE enhancer, abbreviated LSP) and AAV
psuedotype 2/8 LSP.dnMstat was produced. AAV pseudotype 2/
8 has been previously shown to have excellent tropism for the liver
and following intravenous injection demonstrates superior trans-
duction of the liver in comparison to other AAV serotypes [22,23].
The experimental design of the mouse studies is shown in
Figure 1A. C57 Bl/6 mice were treated as neonates (n = 6 control,
n = 6 treated, denoted C57 neonates) or as adults at three months
of age (n = 6 control, n = 6 treated, denoted C57 adults) and
analyzed three months following viral injection. The mdx mouse
model of Duchenne muscular dystrophy was utilized to examine
the effect of myostatin inhibition on the progression of muscular
dystrophy. Levels of dnMstat were assessed in the serum of all mdx
groups at sacrifice (Fig. 1E). At four months of age, there was a
,3 fold increase in circulating inhibitor when mice were treated at
one month of age compared to treatment as neonates. The
difference in circulating inhibitor was maintained throughout the
study, although both injection methods exhibited similar absolute
decreases by eleven months of age. Viral injection in neonatal
animals effectively resulted in a low dose of dnMstat while viral
injection in one month old animals resulted in a high dose of
dnMstat. For the purpose of simplifying discussion, we named the
experimental groups to reflect the age of the animal at the
experimental endpoint and dose of inhibitor. Mdx mice treated at
one month of age and analyzed at four months of age (n = 6
control, denoted mdx 4C and n= 6 treated, denoted mdx 4H). A
small group of mdx mice were injected as neonates and sacrificed at
four months of age to determine the effect of age on viral
expression and were not evaluated further (n = 4 treated, denoted
mdx 4L). For the eleven month endpoint, mice were treated as
neonates (n = 6, denoted mdx 11L) or one month of age (n = 4,
denoted mdx 11H) with a common set of controls (n = 6, denoted
mdx 11C).
The specificity of the LSP was confirmed by intravenous
delivery of 1E12 genome copies of AAV2/8 LSP.GFP. Expression
of GFP was detected exclusively in the liver while no fluorescence
was observed in the heart or skeletal muscle (Fig. 1B). The tissue
distribution of transgene expression was further assessed by reverse
transcriptase polymerase chain reaction in six different tissues.
Expression of the transgene was only detected in the liver
(Fig. 1C). AAV2/8 LSP.dnMstat was injected into the tailvein
of adult C57 Bl/6 mice and high levels of the inhibitor were
detected in the blood as well as the liver after one week (Fig. 1D).
C57 Bl/6 animals were sacrificed one week after viral injection to
assess acute changes in the activity of key intracellular regulators of
muscle growth. In treated quadriceps there was a decrease in
phosphorylated Smad 2/3, a decrease in phosphorylated JNK and
an increase in phosphorylated Akt (n = 4) (Fig. 2). These results
demonstrate that the liver was a viable target for AAV mediated
overexpression of a circulating myostatin inhibitor.
The efficacy of myostatin inhibition by dnMstat was assessed by
analysis of muscle size and function of C57 Bl/6 animals
overexpressing dnMstat. Expression of dnMstat resulted in a 14–
22% increase of muscle mass of the quadriceps, tibialis anterior
Systemic Myostatin Inhibition
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and extensor digitorum longus (EDL) muscles in the C57 adults
group while a 32–43% gain in these muscles was observed in the
C57 neonates group (Table 1). Thus a more pronounced increase
in muscle mass in non-dystrophic animals was observed when
inhibition was initiated early in the lifespan. The wet weight of the
soleus and heart did not change in both C57 Bl/6 groups. In the
C57 adults group, the EDL underwent hypertrophy without
hyperplasia as indicated by a rightward shift in the fiber area
distribution without a change in fiber number (Figs. 3A, b). The
EDL exhibited an approximately 15% increase in cross sectional
area (CSA) and tetanic force (Fig. 3C, D). No change in force
production normalized to CSA (specific force) was observed
(Fig. 3E). Taken together, these data indicate expression of
dnMstat resulted in increased muscle mass, strength and
hypertrophy without hyperplasia of normal skeletal muscle.
To clarify the effect of myostatin inhibition in the soleus, fiber
type distribution was evaluated in the C57 Bl/6 groups. There was
no effect of dnMstat on soleus fiber type in the C57 adults group
Figure 1. Systemic viral delivery and dnMstat expression. The viral construct used in all experiments consists of a liver specific promoter (LSP)
paired with dominant negative myostatin (dnMstat). A similar construct was prepared by substituting GFP for dnMstat. (a) Experimental design for
C57 Bl/6 and mdx groups injected intravenously with AAV 2/8 LSP.dnMstat. The C57 neonates group was injected at day 3–5 of life and sacrificed at
three months of age while the C57 adults group was injected at three months of age and sacrificed at six months of age. The mdx 4H group was
injected at one month of age and sacrificed at four months of age. Themdx 11L and 11H groups were sacrificed at eleven months of age and injected
as neonates (11L) or at one month of age (11H). AAV 2/8 LSP.GFP or AAV 2/8 LSP.dnMstat was injected into the tailvein of adult C57 Bl/6 mice to
assess the specificity of the promoter and to confirm overexpression of dnMstat. (b) Following injection of AAV 2/8 LSP.GFP, GFP fluorescence was
only observed in the liver. (c) Tissue specificity of transgene expression was further assessed by RT-PCR following injection of AAV 2/8 LSP.dnMstat.
RNA was isolated from treated heart (Ht), liver (Li), diaphragm (Dia), quadriceps (Qu), lung (Lu) and kidney (Ki), treated with DNase to remove residual
AAV vector genomes and reverse transcribed. PCR was performed on the resulting cDNA to assess the expression of dnMstat (,450 bp) and beta-
actin as a control (,350 bp). Transgene expression was detected solely in the liver. (d) dnMstat was detected in the serum and liver by
immunoblotting with an antibody directed against the myostatin N-terminus. (e) Serum levels of dnMstat were measured at the experimental
endpoints. Circulating levels of the inhibitor were approximately three times higher in the mdx 4H group than the mdx 4L group. The absolute
difference in expression level was maintained at eleven months of age in the 11L and 11H groups. Note that the mdx 4L group was not analyzed
further Scale bar: 100 mm.
doi:10.1371/journal.pone.0009176.g001
Systemic Myostatin Inhibition
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(Fig. 3F). However there was a shift toward faster fiber types in
the C57 neonates group as 10% of the treated muscle fibers were
MHC type IIB whereas no type IIB fibers were detected in control
muscle.
The mdx groups overexpressing dnMstat demonstrate increased
body weight and wet weight of all muscles examined compared to
age matched controls (Fig. 4A, C, D). The increases in limb
skeletal muscle size were comparable to previously described
approaches to myostatin inhibition [3,13,14]. In the mdx 4H
group, the masses of the tibialis anterior, gastrocnemius and
quadriceps muscle in treated animals were 38%, 34% and 46%
larger than control, respectively (Fig. 4C). The increase in muscle
mass observed in these muscles persisted to eleven months of age
in the mdx 11H group. While the mdx 11L and mdx 11H muscle
weights were not statistically different, both were greater than
control muscle weights and there was a notable trend toward a
larger magnitude of muscle growth when myostatin inhibition was
initiated at one month of age (mdx 11H) in comparison to the
neonatal period (mdx 11L) (Fig. 4D). The heart weight of treated
mdx mice increased by 25% in the mdx 4H group and 22–42% in
the mdx 11L and 11H groups (Fig. 4C, D). The heart/body
weight ratio (mg/g) did not change in the mdx 4H group (460.1 vs
460.3). In the eleven month old groups, control mdx mice had a
heart/body weight ratio of 4.7260.1 which was not significantly
different from the mdx 11H group (4.660.1). The mdx 11L group
had a ratio of 4.260.1 which is less than controls. This is most
likely because the increase in body weight in this group slightly
outpaced the increase in heart weight.
Serum creatine kinase (CK) is a measure of the condition of
whole body skeletal muscle. In mdx mice and humans afflicted by
Duchenne muscular dystrophy the absence of dystrophin leads to
sarcolemmal damage and increased membrane permeability,
thereby elevating serum CK. Myostatin inhibition resulted in a
significant decrease in serum CK levels in the mdx 4H group
compared to age matched control mdx levels (Fig. 4B); however,
serum CK levels in the mdx 11L and 11H groups did not differ
from eleven month old control mdx levels.
Immunohistochemistry was utilized to measure the cross
sectional area (CSA) and to assess the myosin heavy chain
(MHC) composition of muscle fibers from the EDL, soleus and
Figure 2. Signaling changes following short term myostatin inhibition in C57 Bl/6 mice. C57 mice were injected intravenously with AAV
2/8 LSP.dnMstat and after one week the animals were sacrificed. Immunoblotting for total and phosphorylated Smad2/3, Akt and JNK was performed
on protein homogenates of quadriceps muscle using beta-actin as a loading control. In dnMstat treated C57 quadriceps there was a (a) 41% decrease
in phosphorylated Smad 2/3, (b) 59% increase in phosphorylated Akt and (c) 31% decrease in phosphorylated JNK. Data represent mean6SD.
* Statistically significant compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.g002
Table 1. Effect of systemic myostatin inhibition on muscle mass in C57 Bl/6 mice.
Control Adults dnMstat Adults Control Neonates dnMstat Neonates
Body weight (g) 22.760.7a 24.562.2 221.161.5 23.261.8
Quadriceps (mg) 158.1615.6 192.967.9b 145.569.1 208.1637.6b
Tibialis anterior (mg) 40.363.5 45.963.1b 40.261.9 53.961.21b
EDL (mg) 8.160.6 9.460.7b 8.960.4 11.860.4b
Soleus (mg) 8.260.4 8.860.9 7.460.2 8.760.2
Heart (mg) 102.263.2 107.365.1 104.964.2 108.664.9
aData represent mean 6 SD for muscles from sex and age matched control (n = 6) and treated mice (n = 6).
bStatistically significant compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.t001
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diaphragm of the mdx groups. These skeletal muscles were chosen
for analysis to determine if muscle groups with different fiber types
and disease progression respond differentially to myostatin
inhibition. The EDL represents a prototypical ‘‘fast’’ muscle type
consisting of mostly fast glycolytic MHC type IIB fibers and the
soleus represents a prototypical ‘‘slow’’ muscle type well populated
with slow oxidative MHC type I fibers. The diaphragm contains a
mixed fiber type distribution and is the mouse muscle in the mdx
model most representative of human disease [24]. Both limb
muscles exhibited an increase in muscle fiber size without a change
in fiber number, with the exception of the EDL in the mdx 11H
group, which did not hypertrophy (Figs. 5, 6). Fiber sizes were
further classified according to MHC type to determine which fiber
type population accounted for the observed overall hypertrophy.
In accord with prior studies that have found that myostatin
preferentially acts on fast fiber types, the mean CSA of type IIA
and IIB fibers was increased in the EDL while the mean CSA of
only type IIA fibers was increased in the soleus (Figs. 5A, B and
6A, B). The EDL had 11% more type IIB fibers in the mdx 4H
group and 19% more type IIB fibers in the mdx 11H group
(Fig. 5D). Similarly, the soleus had 13% more type IIB fibers in
the mdx 4H group and 20% more type IIA fibers in the mdx 11H
group (Fig. 6D). In both limb muscles there were not significant
differences between the mdx 11L and mdx 11H groups. At both
endpoints there were no differences in the diaphragm fiber size
distribution or sagittal fiber number (Figs. 7A, B, C). The
diaphragm exhibited an increase in type IIx fibers and decrease in
type IIA fibers in the mdx 4H group while no difference in fiber
Figure 3. Effect of systemic myostatin inhibition in C57 Bl/6 mice. Adult female C57 Bl/6 mice were injected intravenously with AAV2/8
LSP.dnMstat and analyzed three months after injection at six months of age (C57 adults). A second group of animals was injected via a subxyphoid
approach at postnatal day 3–5 with the same virus and analyzed at 3 months of age (C57 neonates). The fiber area distribution, fiber number and
functional properties of the EDL were analyzed in the C57 adults group. (a) In the dnMstat group there was a rightward shift in the fiber size
distribution indicative of an increase in fiber area. (b) The number of fibers in the midbelly cross section of the EDL was unchanged. (c-e) There was an
increase in cross sectional area (CSA) of the EDL with a proportionate increase in tetanic force resulting in no change in specific force. (f) The fiber
type distribution of the soleus was unchanged in the C57 adults group while significantly more type IIB fibers were found in the C57 neonates group.
Data represent mean6SD. * Statistically significant compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.g003
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type composition was found in the long term groups (Fig. 7D).
The mdx 11H diaphragm was further analyzed by Masson’s
trichrome staining to assess the extent of connective tissue
infiltration. As shown in Fig. 7E, the proportion of fibrotic area
in the diaphragm was unchanged by long term overexpression of
dnMstat.
The function of the EDL, soleus and diaphragm was assessed to
determine if overexpression of dnMstat enhanced muscle strength.
The mdx 4H EDL exhibited increased absolute tetanic force
production comparable to the increased CSA resulting in no
change in force normalized to CSA (specific force) (Table 2). In
contrast, the mdx 4H soleus generated 55% greater tetanic force
and 66% higher specific force, while force production in the
diaphragm was unchanged (Table 3, Fig. 7E). These data
indicate short term myostatin blockade improved force generation
capacity of the limb muscles (soleus and EDL) but not the heavily
Figure 4. Effect of myostatin inhibition on body weight, serum creatine kinase and muscle weight in mdx mice. (a) Body weight was
increased in all dnMstat treated groups. (b) Serum creatine kinase (CK) was reduced in the mdx 4H group in comparison to four month old mdx
controls (4C), however it was not corrected in themdx 11L andmdx 11H groups in comparison to eleven month oldmdx controls (11C). (c) In themdx
4H group, dnMstat overexpression increased the wet weight of the tibialis anterior (TA), gastrocnemius (GAS) quadriceps (QUAD) and heart. (d) At
eleven months of age in the mdx 11L and 11H groups, these muscles continued to demonstrate increased mass. (e) Immunoblotting of mdx 4H
quadriceps for the myostatin C terminus and beta-actin as a loading control revealed increased mature myostatin C dimer in treated muscles.
Representative bands are shown. Data represent mean6SD. * Statistically significant compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.g004
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utilized diaphragm. At eleven months of age, the soleus continued
to demonstrate increased absolute and specific force generation
and the effect was more pronounced in the mdx 11H group
(Table 3). While CSA was increased in the mdx 11L EDL, tetanic
force production was unchanged (Table 2). The absolute strength
of the EDL was slightly increased in the mdx 11H group, yet the
specific force declined by 21%. The mdx 11H diaphragm did not
demonstrate any difference in force production (Fig. 7E). Thus in
long term groups myostatin inhibition led to significantly improved
force production only in the soleus muscle.
To examine the interplay between myostatin and insulin like
growth factor-I (IGF-I), quadriceps muscle homogenates from the
mdx 4H group were analyzed using immunoblotting for myostatin
and ELISA for IGF-I content. There was an approximately 60%
increase in mature myostatin C-dimer in treated muscles (Fig. 4E)
while there was no difference in IGF-I content (39 ng/g in control
muscles vs. 34 ng/g in treated muscles). This finding is consistent
with the report of IGF-I inducing myostatin expression but not
vice versa [25].
The functional effect of myostatin inhibition on the dystrophic
heart was determined by echocardiography. Eleven month old
control mdx hearts and quadriceps were probed for levels of activin
IIB receptor. The protein levels of activin IIB receptor in these
tissues were similar (Fig. 8A). A myostatin inhibitor dose
dependent increase of wet heart weight and mean cardiomyocyte
CSA was observed in treated animals (Figs. 4C, 4D, 8B). In the
mdx 11H group ejection fraction was reduced by 11% and the left
ventricular free wall was 43% thicker (Fig. 8C). Long term
expression of dnMstat also increased LV diastolic and systolic
internal diameter, which are features of the dilated cardiomyop-
athy inherent to the mdx mouse model that develops gradually over
the lifespan of the animal [26,27].
Discussion
Persistent myostatin inhibition through AAV mediated expres-
sion of a novel myostatin inhibitor from the liver results in
increased skeletal muscle mass in normal and mdx mice. It is
important to note that not only does liver secretion result in body
wide inhibition of myostatin, but it also allows for transgene
stability for long periods of time which may not be possible with
skeletal muscle delivery. Initiating myostatin inhibition in neonatal
mdx animals resulted in a low level of circulating dnMstat while
injection of one month old mdx animals resulted in a higher level
(Fig. 1E). The dose of inhibitor is abbreviated as ‘‘L’’ for low dose
and ‘‘H’’ for high dose which is preceded by the age of the animal
at analysis. In an inhibitor dose dependent manner, skeletal muscle
mass was increased in the mdx 11L and 11H groups. The skeletal
muscle mass gains in our study are comparable to the
administration of myostatin neutralizing antibody or propeptide,
surpass prior studies of AAV mediated systemic myostatin
inhibition and approach the muscle growth observed in mdx/
myostatin knockout transgenic mice [3,13,14,28].
Figure 5. Morphological analysis of the mdx EDL. (a) In the mdx 4H group, the mean fiber size of myosin heavy chain (MHC) type IIA and IIB
fibers increased which led to an overall increase in total fiber size. (b) At eleven months of age, the mdx 11H group did not demonstrate fiber size
differences of either fiber type or total fibers compared to controls. (c) The number of fibers in the midbelly cross section of the EDL in all treated
groups was not different from respective control fiber number. (d) There were 11% more type IIB fibers in themdx 4H group while in themdx 11L and
11H groups there were 16–19% more type IIB fibers. Data represent mean6SD. * Statistically significant compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.g005
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Since evidence indicates myostatin acts on both satellite cells
and adult fibers, increased muscle mass could occur via
hypertrophy of existing myofibers, or via fomation of new fibers
(hyperplasia). In previous studies, the deletion of myostatin by gene
targeting promoted both hypertrophy and hyperplasia of skeletal
muscle, whereas postnatal inhibition of myostatin induced
hypertrophy only. The dual mechanism of increased muscle mass
was also apparent in mdx mice crossed to myostatin null mice
throughout life [7]. In the current study, in all muscles examined,
muscle growth was due to hypertrophy rather than hyperplasia.
This finding supports the notion that the prenatal absence of
myostatin leads to both hypertrophy and hyperplasia in skeletal
muscle, while postnatal inhibition of myostatin promotes muscle
growth primarily by hypertrophy [29–31].
The absence of myostatin in knockout animals has been shown
to skew the fiber type composition of the soleus and EDL toward
faster MHC isoforms [32]. However when anti-myostatin
antibodies were administered to two month old severe combined
immunodeficient mice or myostatin was postnatally inactivated
using a Cre-LoxP system in four month old mice there was no
change in MHC profile of the soleus and EDL [29,32]. Thus this is
the first report of myostatin inhibition leading to an alteration in
the MHC content of postnatal skeletal muscle. Reasons for the
discrepancy between our findings in C57 Bl/6 animals and
previous reports may be due to the efficacy of the inhibitor
modality or the age of the animals when myostatin inhibition was
initiated. Notably, there was a shift toward faster MHC isoforms in
the soleus of the C57 neonates group but not in the C57 adults
group. These results suggest there is a critical period of muscle
development prior to three months of age during which myostatin
can postnatally regulate fiber specification.
Fibertyping of 1 month old mdx soleus revealed 30% type I
fibers and 70% type IIA fibers which is consistent with previous
reports [33–35]. The absence of type IIB fibers at the initiation of
myostatin inhibition at one month of age suggests a novel role for
myostatin in the specification of fiber type. Rather than a selective
survival advantage of fast fiber types, there appears to be an active
switching toward fast MHC isoforms which is likely mediated by a
mechanism acting on existing fibers as fiber number did not
change. A potential mediator of this process is the presence of a
large active satellite cell population. Rapid postnatal muscle
growth in C57 Bl/6 animals is partially driven by the fusion of
satellite cells to existing myofibers while in mdx animals there is a
large scale degeneration-regeneration phase at 4–6 weeks of age
followed by continual replacement of degenerated fibers through-
out adult life. The observation of fiber type switching in neonatal
C57 mice and all mdx animals suggests an activated homogenous
satellite cell pool may contribute to the process of fiber
specification influenced by myostatin. Another possibility is that
there may be separate ‘‘slow’’ and ‘‘fast’’ satellite cell subpopu-
lations and the selective activation of the ‘‘fast’’ subpopulation by
myostatin inhibition may be populating the skeletal muscles with
Figure 6. Morphological analysis of themdx soleus. At the four month (a) and eleven month (b) timepoint myostatin inhibition did not change
the mean fiber size of type I fibers but did increase the mean fiber size of myosin heavy chain (MHC) type IIA and total fibers. (c) Overexpression of
dnMstat did not change the number of fibers in the midbelly cross section of the soleus. (d) In the mdx 4H group, the percentage of type IIB fibers
was increased from 4% to 14%. At eleven months of age there is no significant difference in the percentage of IIB fibers among the experimental
groups. However the mdx 11L and mdx 11H soleus contained 20–21% more type IIA fibers. Data represent mean6SD. * Statistically significant
compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.g006
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Figure 7. Morphological properties and force production of the mdx diaphragm. (a,b) Fiber size distributions were unaltered by myostatin
inhibition in the mdx 4H and mdx 11H groups. (c) The number of fibers across the sagittal plane of the diaphragm, a measure of diaphragm fiber
number, did not change at either time point. (d) In the mdx 4H diaphragm there were more type IIX fibers and less type IIA fibers. No changes in fiber
type were observed in the mdx 11H group. (e) Masson’s trichrome stained diaphragm sections did not demonstrate a difference in fibrotic area in the
mdx 11H diaphragm in comparison to control (11C). (f) Overexpression of dnMstat did not improve specific force production in the diaphragm. Data
represent mean6SD. * Statistically significant compared to control, p,0.05. Scale bar: 50 mm.
doi:10.1371/journal.pone.0009176.g007
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fast fiber types. Alternatively, the observed changes in MHC
isoform expression may be due to direct action on muscle fibers
and not involve satellite cells. Further experiments are necessary to
delineate the mechanism and precise timing of fiber type switching
of normal skeletal muscle induced by myostatin inhibition.
Immunoblotting of C57 Bl/6 muscle one week after viral
injection revealed signaling changes consistent with myostatin
inhibition. When the biologically active form of myostatin engages
the activin IIB receptor an intracellular signaling cascade results in
phosphorylation of Smad 2/3. Phosphorylated Smad 2/3 then
translocates to the nucleus to suppress expression of myogenic
factors and cell cycle progression in satellite cells. Other key
regulators of muscle size have been implicated in the myostatin
signaling pathway such as the serine/threonine kinase Akt and the
MAP kinases ERK, JNK and p38 [25,36–38]. In C57 Bl/6 mice
overexpressing dnMstat there was a decrease in the levels of
phosphorylated Smad 2/3 as was seen in C2C12 cells incubated
with anti-myostatin antibody [3]. In our study there was also a
decrease in JNK phosphorylation and an increase in Akt
phosphorylation following acute inhibition in C57 Bl/6 animals.
In agreement with our observations is a recent study of myotube
hypertrophy which found increased levels of Akt phosphorylation
following adenoviral overexpression of the myostatin propeptide
[39]. These changes suggest muscle growth due to myostatin
inhibition is partially mediated by the Smad 2/3, Akt and JNK
signaling pathways and indicate that myostatin is functionally
inhibited by dnMstat. Unaltered IGF-I content in treated muscles
supports a mechanism of increased Akt phosphorylation achieved
through the inhibition of myostatin rather than increased IGF-I.
Further, the increase in activated myostatin in treated muscle
indicates that under conditions of suppressed myostatin signaling
there may be compensatory upregulation and/or increased local
activation of myostatin to supercede the blockade. The upregula-
tion of myostatin may be mediated through a Smad7 dependent
auto-regulatory loop activated by the blockade of myostatin
signaling [40], but this was not addressed in the current study.
In mdx animals myostatin inhibition was extremely effective at
increasing muscle size and strength in the short term, however
long term analysis yielded mixed results. Previous studies that have
used antibodies directed against myostatin, propeptide injections
or AAV mediated overexpression of an inhibitor have demon-
strated increased muscle mass and absolute force production
following 3–4 months of myostatin inhibition in young animals (1–
3 months old) [3,13,14]. Our analysis of mdx animals at four
months of age following three months of myostatin inhibition is
consistent with previously published data. There was an increase
in the mass of all skeletal muscles examined and both the soleus
and EDL exhibited increased force production. However,
following 10–11 months of dnMstat expression, myostatin
inhibition did not result in functional benefit in the diaphragm
or EDL. This implies myostatin inhibition as monotherapy will not
be sufficient to attenuate dystrophic changes in the most severely
affected skeletal muscles. In the mdx 11H group the treated
diaphragm had equivalent force production and fibrotic replace-
ment of muscle compared to controls (Fig. 7). As the diaphragm is
more heavily utilized than limb muscles in mice it demonstrates
early degenerative changes, progressive loss of contractile function
and ten fold higher collagen content than other skeletal muscles
[24]. Previous long term studies examining the mdx diaphragm in
the context of reduced myostatin signaling have reported some
histological benefit, but have not demonstrated functional
improvement [7,15]. While the mdx/Mstat KO diaphragm
demonstrates improved histopathology at a later timepoint (18
months of age) than examined in this study, it is unclear if the
apparent histological improvement correlates with enhanced
function and if such changes are possible outside the context of
knockout animals. Thus while long term myostatin inhibition
improves mild dystrophy, as represented by the mdx limb muscles,
it does not sufficiently drive muscle growth and reduce muscle
fibroblast activity to compensate for severe dystrophy, as
represented by the mdx diaphragm.
Functional analysis of the slow twitch soleus muscle and fast
twitch EDL muscle revealed divergent effects of long term
myostatin inhibition. The soleus muscle contains fiber types more
representative of human skeletal muscle, and so the observed
increase in specific force maintained in long term groups is an
encouraging finding for clinical translation. This result may be
attributable to a fiber type shift toward faster MHC isoforms.
However, it is not clear if human skeletal muscle will shift in the
same manner. At eleven months of age the mdx 11H EDL had
decreased specific force production. These findings are analogous
to the myostatin knockout mouse which demonstrates reduced
Table 2. Functional properties of EDL muscle in mdx groups.
Mdx 4C Mdx 4H Mdx 11C Mdx 11L Mdx 11H
Mass (mg) 13.962.4a 19.862.2b 16.161 17.961.5b 22.761.4b
CSA (mm2) 2.260.3 2.960.5b 2.560.1 2.760.2b 3.56.02b
Tetanus (mN) 360.4633.9 489630.4b 452.3666 462.6654 516.1658.3b
Specific Force
(N/cm2)
17.161.6 17.761.5 18.263.0 17.161.3 15.061.2b
aData represent mean6SD from male four month old control mdx (n = 6), mdx
4H (n = 6), eleven month old control mdx (n = 6), mdx 11L (n = 6) and mdx 11H
(n = 4).
bStatistically significant compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.t002
Table 3. Functional properties of soleus muscle in mdx groups.
Mdx 4C Mdx 4H Mdx 11C Mdx 11L Mdx 11H
Mass (mg) 12.462.7a 16.462.5b 11.461.1 17.761.0b 18.262.1b
CSA (mm2) 2.160.7 1.860.2 2.160.2 3.160.3b 360.3b
Tetanus (mN) 160.6635.4 248.6632.4b 158.1620.4 268.1619.7b 325.2633.0bc
Specific Force (N/cm2) 8.363.0 13.862.3b 7.761.5 8.761.2 10.962.4b
aData represent mean6SD from male four month old control mdx (n = 6), mdx 4H (n = 6), eleven month old control mdx (n = 6), mdx 11L (n = 6) and mdx 11H (n = 4).
bStatistically significant compared to control, p,0.05.
cStatistically significant compared to mdx 11L, p,0.05.
doi:10.1371/journal.pone.0009176.t003
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specific force of the EDL but not the soleus [41,42]. The exact
etiology of reduced specific force output in the EDL is currently
unknown. The documented abnormalities of the myostatin
knockout EDL, such as a decrease in the number of mitochondria
per fiber [41], are not sufficient to explain a drop in specific force
production. Modulation of the TGF- b/Smad signaling pathway
in myostatin knockout mice or long term inhibition in mdx mice
results in reduced specific tension of the EDL that is of
questionable therapeutic utility [41]. This effect appears to be
confined to fast fiber types as the soleus had increased specific
force in mdx groups. Further experiments are required to identify
the mechanism of fiber type dependent impaired force generation
due to myostatin blockade.
The lack of hypertrophy of type I fibers in response to myostatin
inhibition in mice predicts that in humans a treatment that solely
blocks myostatin regardless of modality will be much less effective
than in preclinical mouse studies. In comparison to rodents human
skeletal muscle has far fewer fast fibers and predominately consists
of slow fibers. For example, the human soleus is entirely composed
of type I fibers while mouse soleus consists of approximately 60%
IIA fibers and 40% I fibers [43]. Importantly, human locomotor
skeletal muscle does not contain type IIB fibers [44]. Type IIB
fibers contain the highest density of activin IIB receptors,
endogenous myostatin promoter activity and expression of
myostatin in normal muscle [42,45]. Therefore type IIB fibers
are presumably the most responsive to myostatin mediated
signaling. In this study we demonstrate that IIA fibers also
undergo hypertrophy in response to myostatin inhibition in the
soleus and EDL. This effect is critical for human therapy, as in
concert with a fiber type shift to faster MHC isoforms hypertrophy
of IIA fibers could lead to increased force production despite the
near absence of fiber types most responsive to myostatin
inhibition.
It is imperative to establish the safety of myostatin inhibition on
the dystrophic heart because cardiomyopathy is nearly ubiquitous
by 18 years of age in humans with Duchenne muscular dystrophy
[46]. The absence of myostatin has been previously reported to
have no effect on heart function in myostatin knockout animals or
mdx/Mstat KO transgenics [47,48].The studies addressing this
issue have been either short term or relied on genetic crosses which
have limited clinical relevance. Wagner et al. crossed mdx animals
with myostatin knockout animals and did not observe any change
in heart size or functional parameters at 24 months of age in mdx/
Mstat KO animals [48]. However, the mdx mice in this study did
not develop dilated cardiomyopathy at 24 months of age as mdx
mice were indistinguishable from normal C57 Bl/6 controls across
functional parameters. The absence of dilated cardiomyopathy in
old mdx mice is in contrast to other studies in which
echocardiographic changes suggestive of DCM have been first
noted at 9–11 months of age and progress to a severe decline in
ejection fraction to 35% at 21 months of age [26,27,49,50]. In our
study, myostatin inhibition did not affect heart weight in normal
animals. However in treated mdx animals there was a 20% increase
in heart weight at four months of age and a 40% increase in heart
weight at eleven months of age. It is not likely that the increased
heart weight is simply due to an increase in size in proportion to
body weight. Barton et al. examined mdx mice that overexpressed
the positive growth factor IGF-I only in skeletal muscle without
systemic effects [12]. In this study an increase in skeletal muscle
mass and body weight were observed without altering heart
weight.
While the impact of myostatin inhibition on the progression of
dilated cardiomyopathy in the mdx mouse or in more severe
dystrophic cardiomyopathy is unknown, further investigation is
necessary prior to implementing myostatin based therapies to treat
disease conditions that include cardiac involvement. Differences in
heart size or function in the mdx model following myostatin
inhibition may not have been observed previously due to less
effective myostatin inhibition or short term treatment regimens
[3,13,14]. A possible mechanism for the observed cardiac
hypertrophy is reduced myostatin signaling through the activin
IIB receptor which is expressed at similar levels in the heart
compared to skeletal muscle (Fig. 8A). Prior reports of the
involvement of myostatin in cardiac remodeling include the
upregulation of myostatin in cardiomyocytes bordering an
infarcted region in sheep heart and in the left ventricle of volume
overloaded rat heart [51,52]. These data suggest that while
myostatin is not involved in regulation of cardiomyocyte size in the
normal heart it may be an important negative regulator of
cardiomyocyte size under pathological conditions that trigger
Figure 8. Cardiac properties in long term mdx mice. (a) Protein levels of the activin IIB receptor were similar in the mdx heart and quadriceps.
(b) Increased mean cardiomyocyte cross sectional area (CSA) was noted in the mdx 11L and 11H groups. (c) Echocardiography demonstrated
increased left ventricle internal diameter during diastole (LVIDd), increased left ventricle internal diameter during systole (LVIDs), increased left
ventricle (LV) free wall diameter and decreased ejection fraction in treated animals. There was no difference between the mdx 11L and 11H groups
across the reported parameters. Both groups were significantly different from control (11C). Data represent mean6SD. *Statistically significant
compared to control, p,0.05.
doi:10.1371/journal.pone.0009176.g008
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cardiac remodeling. Loss of myostatin signaling in these conditions
may result in acceleration of cardiomyocyte hypertrophy and
ultimately progression to heart failure. Further studies are needed
to determine how the observed alterations in heart mass and
function evolve over time.
Liver mediated overexpression of dnMstat has several important
advantages over prior experimental approaches aimed at inhib-
iting myostatin. A clinical trial utilizing a neutralizing antibody
directed at myostatin did not improve muscle function or increase
muscle mass in adult patients with muscular dystrophy [53]. If
implemented into clinical practice, any approach that involves
injection of protein based inhibitors such as an antibody,
myostatin propeptide or soluble activin IIB receptor would
necessitate lifelong therapy while the use of AAV based inhibitors
delivered to the liver requires only a single injection to achieve
high levels of persistent transgene expression. There is limited
possibility of immune recognition of the transgene product as
dnMstat is identical to the endogenous propeptide with the
exception of a single point mutation. In addition, there is evidence
that liver production and secretion may induce tolerance to a
foreign peptide [54]. The activin IIB receptor approach and other
non-myostatin specific binding proteins such as follistatin may
have limited clinical applicability since TGF-beta signaling in
multiple organ systems may be impaired due to the broad tissue
distribution of the activin IIB receptor [55].
Liver transduction also avoids the technical hurdle of direct
transduction of dystrophic muscle and offers indefinite systemic
delivery of therapeutic transgenes. In addition to the inherent
difficulty of gene transfer to the entire musculature in large animal
models and humans, long term transduction of dystrophic muscle
by AAV without membrane stabilization is not feasible (unpub-
lished observations by E.R. Barton and H.L. Sweeney, [20,21]).
This observation is contrary to a report describing myostatin
inhibition following intramuscular injection of AAV 2/1 for over
two years [15]. However there was no evidence presented that the
transgenes were present in circulation or muscle at the study
endpoint. Another possibility is that the liver was transduced in
addition to short term limb muscle transduction as the promoter
used in this study was not identified.
Our approach could be translated to larger animals by
engineering species appropriate transgenes. The canine models
of Duchenne muscular dystrophy more accurately recreate the
clinical course of human disease than the mdx mouse and the liver
has been successfully therapeutically transduced by AAV in a
canine model of hemophilia B [56–59]. The dystrophic canine
may be a more predictive indicator of the possible human efficacy
of dnMstat than the mdx mouse. Even when the serum levels of the
inhibitor were relatively low in the mdx 11L group, impressive
gains in skeletal muscle mass and fiber type switching were
observed. Myostatin inhibition via liver targeted gene transfer is
highly adaptable to future gene therapy studies and has the
potential to attenuate muscular dystrophy in large animal models.
Methods
Vector Production
The myostatin gene was isolated from mouse cDNA and the C
terminal region from nucleotide 825–1131 of the reading frame
was deleted via PCR. Splicing by overlap extension PCR was then
used to introduce a D76A mutation that results in a peptide
resistant to proteolytic activation. The resulting mutant transgene
was named dominant negative myostatin (dnMstat) and was
cloned into an AAV transfer vector with a liver specific promoter
(a1-antitrypsin promoter with ApoE enhancer, kindly provided by
Dr. Katherine High). The LSP has been used previously to express
Factor IX from the liver of mice [57]. In addition, a control vector
was cloned containing the LSP and green fluorescent protein
(GFP). AAV pseudotype 2/8 was produced by the University of
Pennsylvania Vector Core as previously described [22].
Viral Injection of Mice
The virus used in all experiments was AAV2/8 LSP.dnMstat.
The delivery method varied according to the age of the animal
being treated. Neonatal mice were injected via a subxyphoid
approach with 1E12 GC of virus following cryosedation as
described previously [60]. To deliver virus to the liver of adult
mice, intravenous tailvein injection was performed. Animals were
sedated with a ketamine-xylazine mixture. Following sedation
1E12 genome copies of virus diluted in 300 ul saline was delivered
into the tail vein. Non-viral controls were injected with 300 ul
saline. Animals were sacrificed at the designated endpoints and the
muscles frozen for histology, biochemical or functional analysis.
All mouse experiments were approved by the University of
Pennsylvania Animal Care and Use Committee.
RT-PCR for Transgene Expression
The heart, diaphragm, liver, quadriceps, lung and kidney were
dissected from mice two weeks post viral injection to assess the
tissue specificity of the liver specific promoter. Tissues were
crushed on a mortar and pestle cooled by dry ice and total RNA
was isolated from muscle homogenates by RNA TRIZOL
extraction (Gibco-BRL). Extracted RNA was treated with DNase
(Ambion) to remove residual AAV genomes that may interfere
with PCR analysis. 150 ng of RNA from each sample was
subjected to single strand reverse transcription and the resulting
cDNA was used in a PCR reaction with Taq polymerase (Applied
Biosystems, Foster City, CA). The primers for dnMstat were
forward 59 AGG-CAC-TGG-TAT-TTG-GCA-GA 39 and reverse
59 GAA-CCT-GAA-ACA-TAA-AAT-GA 39. The primers for
beta-actin were forward 59 ATC-ACT-ATT-GGC-AAC-GAG-
CG 39 and reverse 59 ACT-CAT-CGT-ACT-CCT-GCT-TG 39.
The resulting PCR reactions were run on a 2% agarose gel with
ethidium bromide and visualized under UV light.
Muscle Morphology
For morphological analysis muscles were embedded in Optimal
Cutting Temperature compound (Sakura Finetek, Torrance, CA)
and frozen in liquid nitrogen cooled isopentane. Ten micron thick
sections were cut and the resulting slides were stored at 220uC.
Immunohistochemistry was employed to determine the fiber sizes,
fiber number and myosin heavy chain (MHC) composition of
examined muscles as described previously [12]. The myosin heavy
chain (MHC) antibodies used to determine the MHC composition
of selected muscles were type I (BA-F8) at 1:50, type IIA (SC-71) at
1:10 and type IIB (BF-F3) at 1:3. Sections were blocked in
5%BSA/PBS and then incubated overnight in 5%BSA/PBS
containing in a rabbit anti-laminin monoclonal antibody diluted
1:100 (Neomarkers, Fremont, CA) and a MHC primary antibody
at the dilutions described above. Following washes in PBS, sections
were incubated in appropriate secondary antibodies (Invitrogen,
Carlsbad, CA) for one hour in the dark at room temperature.
Slides were washed and mounted with Vectashield with DAPI. All
images were captured and processed on a Leitz DMRBE
fluorescent microscope (Leica, Bannockburn, IL) equipped with
a MicroMAX digital camera system (Princeton Instruments,
Trenton, NJ). Open Lab imaging software (Improvision, Wal-
tham, MA) was used for further analysis.
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Immunoblotting
For Western blotting muscles were dissected, weighed and snap
frozen in liquid nitrogen. Muscles were crushed in a mortar and
pestle on dry ice. Samples were then homogenized in lysis buffer
[5 mM EDTA pH=8, 50 mM Tris Cl pH 8,150 mM NaCl,
0.1% SDS, 1% Triton X-100, 0.5% deoxycholate, 50 mM
dithiothreitol and Complete Protease Inhibitor Cocktail (Roche,
Indianapolis, IN)]. Following incubation on ice for 10 min the
protein homogenates were centrifuged at 12,000 RPM for 10 min.
The supernatant was used for subsequent Western blotting.
Protein concentration was determined by the Bio-Rad Protein
Assay (Bio-Rad, Hercules, CA). 50 ug of protein or 1.5 mL of
serum was mixed with 2x SDS loading buffer [130 mM Tris,
pH=8, 20% glycerol, 4.6% SDS, 2% DTT, 0.02% bromophenol
blue], denatured at 95u for ten minutes and loaded onto 4–20%
PAGEr Gold Precast Gels (Lonza, Rockland, ME). Proteins were
transferred via the iBlot Dry Blotting System onto nitrocellulose
membranes (Invitrogen, Carlsbad, CA). The membrane was then
blocked with 5% non fat dry milk in Tris buffered saline
containing 0.05% Tween 20. Immunoblotting was performed to
detect myostatin N terminus (1:1000, kindly provided by Dr. Se
Jin Lee), phospho-Smad 2/3 (1:500, Millipore, Temecula, CA),
Smad 2/3 (1:1000, Cell Signaling Technology, Danvers, MA),
activin IIB receptor (1:500, Sigma, St. Louis, MO), phospho-Akt
and total Akt (1:1000, Cell Signaling Technology, Danvers, MA),
phospho-JNK and total JNK (1:1000, Cell Signaling Technology,
Danvers, MA), and actin (1:2000, Sigma, St. Louis, MO).
Appropriate horseradish peroxidase conjugated secondary anti-
bodies were used at twice the dilution of the primary antibody (GE
Healthcare, UK). Protein detection was performed by exposure to
Super Signal West Pico Chemiluminescent Substrate kit (Pierce,
Rockford, IL) and the band intensity was processed using
densitometry software (Alpha Innotech, San Leandro, CA).
Muscle Functional Analysis
The contractile properties of the soleus, extensor digitorum
longus (EDL) and diaphragm muscle were measured. Mice were
anesthetized with ketamine/xylazine (80 and 10 mg/kg body wt,
respectively) and exsanguinated. Blood samples were allowed to
clot, centrifuged at 20006g for 20 minutes, and then stored at
280uC for creatine kinase measurement and immunoblotting.
The EDL, soleus, diaphragm, and gastrocnemius muscles were
removed, placed in a bath of Ringers solution gas-equilibrated
with 95% O2/5% CO2. and were subjected to isolated mechanical
measurements using a previously described apparatus (Aurora
Scientific, Ontario, Canada) [61]. After determining optimum
length (Lo) by supramaximal twitch stimulation, maximum
isometric tetanus was measured. Upon completion of these
measurements, muscles were weighed and rapidly frozen in
melting isopentane for morphological analysis.
In Vivo Transthoracic Echocardiography
M-mode echocardiography was performed on mdx animals at
eleven months of age under ketamine/xylazine anesthesia using a
15-MHz phased-array probe connected to a Sonos 7500
echocardiographic machine (Philips Medical Imaging, Andover,
Massachusetts). In brief, an M-mode cursor was positioned in the
parasternal short-axis view perpendicular to the interventricular
septum and posterior wall of the LV at the level of the papillary
muscles, and M-mode images were obtained for measurement of
LV end-diastolic and end-systolic dimension (LVDd and LVDs).
The percentage of fractional shortening (%FS) was calculated from
the equation %FS = [(LVDd–LVDs)/LVDd] x 100. The end
diastolic and end systolic volumes, ejection fraction, cardiac output
and stroke volume were calculated using the Teicholtz formulas
[62]. The same sonographer (MS) was blinded to the treatment
groups of the mice, performed all studies and the resulting
calculations.
Statistical Analysis
Comparison of means from each experimental group was
accomplished by two tailed unpaired Student’s t-test or one-way
ANOVA with Student-Newman-Keuls post hoc analysis as
appropriate. Numerical data is reported as mean 6 standard
deviation. P values ,0.05 were accepted as significant.
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